argenx (ARGX) Scheduled to Post Quarterly Earnings on Thursday

argenx (NASDAQ:ARGX) will be releasing its earnings data before the market opens on Thursday, October 31st. Analysts expect argenx to post earnings of $0.10 per share for the quarter.

argenx (NASDAQ:ARGX) last issued its quarterly earnings results on Thursday, July 25th. The company reported $0.45 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.89) by $1.34. argenx had a negative return on equity of 7.33% and a negative net margin of 12.31%. The firm had revenue of $489.43 million for the quarter, compared to analyst estimates of $436.66 million. During the same period last year, the company earned ($1.69) EPS. On average, analysts expect argenx to post $0 EPS for the current fiscal year and $5 EPS for the next fiscal year.

argenx Price Performance

NASDAQ ARGX opened at $557.92 on Thursday. The company has a market cap of $33.16 billion, a P/E ratio of -98.57 and a beta of 0.63. argenx has a 12 month low of $327.73 and a 12 month high of $571.97. The company has a 50-day moving average of $533.68 and a 200-day moving average of $457.45.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on ARGX shares. Guggenheim reaffirmed a “buy” rating and set a $585.00 price target on shares of argenx in a research note on Thursday, September 26th. Raymond James reiterated a “strong-buy” rating and issued a $605.00 target price on shares of argenx in a report on Thursday, October 10th. Deutsche Bank Aktiengesellschaft downgraded argenx from a “buy” rating to a “hold” rating in a research report on Friday, October 4th. Wells Fargo & Company lifted their price objective on argenx from $543.00 to $547.00 and gave the company an “overweight” rating in a research note on Friday, July 26th. Finally, JPMorgan Chase & Co. increased their target price on shares of argenx from $500.00 to $640.00 and gave the stock an “overweight” rating in a research report on Friday, August 23rd. Four research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $550.44.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.